A growing number of lawsuit have been filed by people with hepatitis C whose health insurers denied coverage for Sovaldi, a new drug that can cure over 90% of patients.
Gilead Rakes in Profits as Hepatitis C Patients Seek Treatment
Gilead Sciences gained approval for Sovaldi in October 2013. Since then, it has rapidly become a blockbuster drug, generating $10 billion in 2014 alone.
While Gilead rakes in massive profits, people with hepatitis C are struggling to get coverage from their health insurance companies. Because Sovaldi is so expensive, health insurers are restricting it to patients with extreme liver damage. As a result, only a tiny fraction of the estimated 3.2 million Americans with hepatitis C are getting the treatment they need.
Sovaldi Class Action Lawsuit Filed in Pennsylvania
In December 2014, Gilead was hit with a federal class action lawsuit by the Southeastern Pennsylvania Transportation Authority (SEPTA). SEPTA accuses Gilead of “price gouging” by charging exorbitant fees for Sovaldi. The company has spent about $2.4 million to provide Sovaldi for employees and retirees, the Wall Street Journal reports.